Becton Dickinson and Co vs Thomson Reuters Corp — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $42.39B), while Thomson Reuters Corp trades at $94.22 (market cap $40.96B). The key difference: Becton Dickinson and Co and Thomson Reuters Corp are close in size by market cap, and Thomson Reuters Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| BDX | TRI | |
|---|---|---|
Market Cap | $42.39B | $40.96B |
Sector | Health | Industrials |
52-Week High | $185.39 | $211.14 |
52-Week Low | $135.49 | $76.55 |
Enterprise Value | $58.85B | $42.92B |
Dividend Yield | 2.73% | 2.78% |
Trailing returns across standard periods
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →